TNXPNasdaqPharmaceutical PreparationsFiscal year ends December 31

Tonix Pharmaceuticals Holding Corp.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026

$5.73−0.31 (-5.13%)

Close on Oct 19, 2026

Market cap: $95.32M
P/E (TTM): –
Dividend yield: –

Tonix Pharmaceuticals Holding Corp. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31
Revenue	13	10	7.77	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Cost of Revenue	6.64	7.77	4.74	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Gross Profit	6.47	2.33	3.03	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Research & Development	44	40	87	82	69	36	18	18	13	29	36	19	4.65	2.58	1.16	0.58	–	–
Selling, General & Admin	88	40	35	30	–	–	–	–	–	–	–	–	–	–	–	–	–	–
General & Administrative	–	–	–	30	23	14	11	8.76	7.95	10	13	9.04	6.24	4.08	2.22	1.34	–	–
Advertising Expenses	25	0.20	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Operating Expenses	–	–	–	–	–	–	–	–	–	–	48	28	11	6.66	3.38	1.93	–	–
Total Costs & Expenses	139	147	126	112	92	51	29	26	21	39	48	–	–	–	–	–	–	–
Operating Income	-126	-137	-118	-112	-92	-51	-29	-26	-21	-39	-48	-28	-11	-6.66	-3.38	-1.93	–	–
Interest Expense	0.09	1.23	–	–	–	–	–	–	–	–	–	–	–	0.00	–	–	–	–
Interest & Investment Income	4.15	0.02	1.72	1.87	0.03	0.05	0.21	0.23	0.17	0.13	0.11	–	–	–	–	–	–	–
Other Non-Operating Income	-3.30	-0.87	1.72	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Asset Impairment Charges	–	59	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	–	–	0.06	–	–	–	–	–	–	-0.13	–	–	–	–	–	–	–	–
Pretax Income	–	–	–	–	–	–	–	–	-21	-39	-48	-28	-11	–	–	–	–	–
Net Income	-124	-130	-117	-110	-92	-50	-29	-26	-21	-39	-48	-28	-11	-9.45	-3.47	-1.96	-0.22	-0.20
Preferred Dividends	–	–	–	–	–	1.26	2.47	3.27	–	–	–	–	–	–	–	–	–	–
Net Income to Common	-124	-130	-117	-117	-92	-52	-31	-29	-21	–	–	–	–	–	–	–	–	–
EPS (Basic)(per share)	-14.57	-176.60	-14,720.25	-2,001.00	-810.00	-1,732.50	-60,889.50	-818,527.50	-99,823.50	-485,415.00	-901,530.00	-872,550.00	-1,061,550.00	-1,757,700.00	-1,020,600.00	-1,134,000.00	–	–
EPS (Diluted)(per share)	-14.57	-176.60	-14,720.25	-2,001.00	-810.00	-1,732.50	-60,889.50	-818,527.50	-99,823.50	-485,415.00	-901,530.00	-872,550.00	-1,061,550.00	-1,757,700.00	-1,020,600.00	-1,134,000.00	–	–
Shares Outstanding (Basic, Weighted)(shares)	8.51	0.74	0.01	0.06	0.11	0.03	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	–	–	–
Shares Outstanding (Diluted, Weighted)(shares)	8.51	0.74	0.01	0.06	0.11	0.03	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	–	–	–
EBITDA	-124	-133	-114	-111	-92	-50	-29	-26	-21	-39	-48	-28	-11	–	–	–	–	–
Net Interest Income	–	–	–	–	–	–	–	–	–	–	0.11	0.04	0.00	-1.61	-0.09	-0.04	–	–
Provision for Credit Losses	0.03	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 83.8%
Operating margin: -568.4%
Net margin: -548.6%
Return on equity, FY2025: -64.5%

Financial strength

Current ratio: 6.61
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 572.5%

Valuation

P/E ratio: –
Price to sales: 3.28
Price to book: 0.43
Dividend yield: –